Morita A, Kobayashi N, Choe H, et al. - This study designed to evaluate the impact of switching administration of alendronate after teriparatide for the prevention of bone mineral density (BMD) loss around the implant after total hip arthroplasty. Individuals were assigned randomly into three groups, those switched to alendronate after teriparatide, those receiving continuous alendronate, and control untreated patients and followed up for 2  years after total hip arthroplasty (THA). They assessed baseline periprosthetic BMD by dual-energy x-ray absorptiometry 1  week after THA, followed by subsequent measurements at 1 and 2 years postoperatively. They further analyzed number BMD at preoperatively, 1 and 2  years postoperatively. They recorded a significant effect of switching therapy on BMD of the lumbar spine and zones 1 and 7 at 2  years postoperatively. At zone 1 in particular, it was reported to be more useful than ALD alone.